Cartherics Secures Grant to Propel Ovarian Cancer Therapy

December 19, 2024 06:25 PM AEDT | By Team Kalkine Media

Google News:

Cartherics Secures Grant to Propel Ovarian Cancer Therapy — Image source: Shutterstock

Recent News

Yep AI Launches 24/7 AI Sales Agent on Shopify App Store

Spring 2025 Roundtable Recap: Advancing Beverage Environmental Sustain...

Patricia Corsi Named to Forbes World's Most Influential CMOs for...

Construction Adhesives Market Expansion New Developments and Trends by...

Highlights

Cartherics receives a grant for advancing ovarian cancer therapy.

The funding boosts clinical manufacturing of CTH-401 treatment.

Integrated facility supports seamless transition to human trials.

Cartherics, an Australian biotechnology company, has been awarded a significant grant to advance the clinical manufacturing of its lead ovarian cancer treatment, CTH-401. The $456,000 grant will support Cartherics’ upcoming clinical trials, further enhancing its integrated research and development initiatives.

The grant is part of a broader funding initiative valued at $30.4 million by ScaleReady, Wilson Wolf Manufacturing, and CellReady, aimed at accelerating innovation in cell-based therapies. For Cartherics, this financial boost will enable the purchase of essential equipment and reagents to facilitate its research and manufacturing programs.

CTH-401, a promising therapeutic candidate, has shown remarkable pre-clinical success, with trials on mice demonstrating complete eradication of human ovarian cancer cells. This achievement highlights the potential of Cartherics’ approach to developing allogenic CAR-iNK (CAR-induced Natural Killer) cells as off-the-shelf cancer treatments.

The company’s Melbourne-based integrated facility streamlines its processes, enabling seamless transitions from research to manufacturing. According to Cartherics’ CEO, Professor Alan Trounson, this approach strengthens the company’s ability to bridge the gap between pre-clinical research and clinical applications.

“Streamlining our product development and manufacturing under one roof is an ambitious step. It allows us to transition smoothly from pioneering pre-clinical research to clinical manufacturing,” said Professor Trounson.

The funding also reflects the broader support for Cartherics’ innovative cell-based immunotherapies. Wilson Wolf and CellReady CEO John Wilson emphasized the potential impact of the G-Rex platform, stating that it is ideal for the large-scale manufacturing of Cartherics’ CAR-iNK cells.

Cartherics’ portfolio includes CAR-T and CAR-NK therapies, with a primary focus on addressing challenging cancers like ovarian cancer. By leveraging this grant, the company aims to optimize its manufacturing processes and prepare CTH-401 for human trials, a critical step toward addressing unmet medical needs in cancer treatment.

With promising pre-clinical results and a robust manufacturing strategy, Cartherics (CHT) is poised to advance the development of innovative cancer therapies, marking an important milestone in the fight against ovarian cancer.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.